Enzene CEO On Biosimilar Denosumab And Cetuximab; Medicare Negotiation Impact On US Market

Considering ADCs, RNA therapeutics

11 Sep 2023

CEO of Enzene Biosciences weighs in on the impact of Medicare negotiations in the US on the biosimilars market even as a US filing is planned for a Prolia biosimilar. In the interview, he says Enzene “is not afraid or concerned” over ongoing litigation with Merck KGaA over an Erbitux biosimilar in India, adding that new modalities like ADCs are being “seriously” considered.

Enzene Biosciences, a subsidiary of Alkem Laboratories Ltd, plans a regulatory filing in the US for a biosimilar to Amgen, Inc.’s blockbuster osteoporosis drug Prolia (denosumab). Having tied up with Theramex for the European market and Australia, the move is a bid to expand the biosimilar’s geographical reach.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

First Quarter M&A Activity Rose On The Strength Of Three Deals

10 Apr 2025

• By Joseph Haas

The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

10 Apr 2025

• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

09 Apr 2025

• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.

Trump’s Tariffs Add To European Warning Of $100bn US Exodus

09 Apr 2025

• By Andrew McConaghie

European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

09 Apr 2025

• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.